Regorafenib combined with immune checkpoint inhibitors versus regorafenib monotherapy as a late-line treatment for metastatic colorectal cancer: a single-center, retrospective cohort study.

IF 2 4区医学 Q3 GASTROENTEROLOGY & HEPATOLOGY

Journal of gastrointestinal oncology Pub Date : 2024-08-31 Epub Date: 2024-08-28 DOI:10.21037/jgo-24-468

Can Chen, Xi Luo, Wenhua Tang, Haofei Geng, Julia Martínez-Pérez, Timothy Price, Lili Kang, Honglian Lu, Yanling Zhang

{"title":"Regorafenib combined with immune checkpoint inhibitors versus regorafenib monotherapy as a late-line treatment for metastatic colorectal cancer: a single-center, retrospective cohort study.","authors":"Can Chen, Xi Luo, Wenhua Tang, Haofei Geng, Julia Martínez-Pérez, Timothy Price, Lili Kang, Honglian Lu, Yanling Zhang","doi":"10.21037/jgo-24-468","DOIUrl":null,"url":null,"abstract":"Background: Few data are available on metastatic colorectal cancer (mCRC) treated with late-line regorafenib monotherapy or combined with other therapies. This study thus aimed to examine regorafenib combined with immune checkpoint inhibitors (ICIs) compared with regorafenib monotherapy in patients with advanced CRC.Methods: This single-center retrospective cohort study included patients with advanced CRC who experienced recurrence and progression after standard first- and second-line treatments treatment from November 2018 to December 2021. The patients received regorafenib plus ICIs or regorafenib monotherapy. Treatment response was evaluated based on Response Evaluation Criteria in Solid Tumors (RECIST). Overall survival (OS) and progression-free survival (PFS) were analyzed via multivariate analysis.Results: The combined group and the monotherapy group included 30 and 43 patients, respectively. The median OS (13.7 vs. 10.1 months; P=0.10) and PFS (4 vs. 3.6 months; P=0.32) were not significantly different between the two groups. In males, the median OS was significantly longer in the combined group compared with the monotherapy group (not reached vs. 8.03 months; P=0.02), but the median PFS showed no significant difference (7.23 vs. 3.90 months; P=0.16). There was no significant difference in OS (P=0.71) or PFS (P=0.89) in females. Eastern Cooperative Oncology Group performance status (ECOG PS) 1 [vs. 0; hazard ratio (HR) =3.13, 95% confidence interval (CI): 1.61-6.10; P<0.001] was independently associated with PFS. ECOG PS 1 (vs. 0; HR =3.63, 95% CI: 1.54-8.56; P=0.003) and combined therapy (vs. monotherapy; HR =0.47, 95% CI: 0.22-0.99; P=0.048) were associated with OS.Conclusions: Regorafenib combined with ICIs led to numerically longer PFS and significantly prolonged OS in patients with mCRC compared to regorafenib monotherapy, especially in male patients.","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"15 4","pages":"1497-1507"},"PeriodicalIF":2.0000,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11399868/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of gastrointestinal oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/jgo-24-468","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/28 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Few data are available on metastatic colorectal cancer (mCRC) treated with late-line regorafenib monotherapy or combined with other therapies. This study thus aimed to examine regorafenib combined with immune checkpoint inhibitors (ICIs) compared with regorafenib monotherapy in patients with advanced CRC.

Methods: This single-center retrospective cohort study included patients with advanced CRC who experienced recurrence and progression after standard first- and second-line treatments treatment from November 2018 to December 2021. The patients received regorafenib plus ICIs or regorafenib monotherapy. Treatment response was evaluated based on Response Evaluation Criteria in Solid Tumors (RECIST). Overall survival (OS) and progression-free survival (PFS) were analyzed via multivariate analysis.

Results: The combined group and the monotherapy group included 30 and 43 patients, respectively. The median OS (13.7 vs. 10.1 months; P=0.10) and PFS (4 vs. 3.6 months; P=0.32) were not significantly different between the two groups. In males, the median OS was significantly longer in the combined group compared with the monotherapy group (not reached vs. 8.03 months; P=0.02), but the median PFS showed no significant difference (7.23 vs. 3.90 months; P=0.16). There was no significant difference in OS (P=0.71) or PFS (P=0.89) in females. Eastern Cooperative Oncology Group performance status (ECOG PS) 1 [vs. 0; hazard ratio (HR) =3.13, 95% confidence interval (CI): 1.61-6.10; P<0.001] was independently associated with PFS. ECOG PS 1 (vs. 0; HR =3.63, 95% CI: 1.54-8.56; P=0.003) and combined therapy (vs. monotherapy; HR =0.47, 95% CI: 0.22-0.99; P=0.048) were associated with OS.

Conclusions: Regorafenib combined with ICIs led to numerically longer PFS and significantly prolonged OS in patients with mCRC compared to regorafenib monotherapy, especially in male patients.

查看原文本刊更多论文

瑞戈非尼联合免疫检查点抑制剂与瑞戈非尼单药作为转移性结直肠癌晚期治疗的对比：一项单中心回顾性队列研究。

背景：关于晚期转移性结直肠癌（mCRC）接受瑞戈非尼单药治疗或与其他疗法联合治疗的数据很少。因此，本研究旨在探讨瑞戈非尼联合免疫检查点抑制剂（ICIs）与瑞戈非尼单药治疗晚期 CRC 患者的比较：这项单中心回顾性队列研究纳入了2018年11月至2021年12月期间经过标准一线和二线治疗治疗后出现复发和进展的晚期CRC患者。患者接受瑞戈非尼加 ICIs 或瑞戈非尼单药治疗。治疗反应根据实体瘤反应评估标准（RECIST）进行评估。通过多变量分析对总生存期（OS）和无进展生存期（PFS）进行分析：结果：联合治疗组和单一治疗组分别有30名和43名患者。两组患者的中位 OS（13.7 个月 vs. 10.1 个月；P=0.10）和 PFS（4 个月 vs. 3.6 个月；P=0.32）无显著差异。在男性患者中，联合治疗组的中位OS明显长于单一治疗组（未达8.03个月 vs. 8.03个月；P=0.02），但中位PFS无明显差异（7.23个月 vs. 3.90个月；P=0.16）。女性患者的OS（P=0.71）或PFS（P=0.89）无明显差异。东部合作肿瘤学组表现状态（ECOG PS）1[vs.0；危险比（HR）=3.13，95%置信区间（CI）：1.61-6.10；Pvs.0；HR=3.63，95% CI：1.54-8.56；P=0.003]和联合治疗（vs.单药治疗；HR=0.47，95% CI：0.22-0.99；P=0.048）与OS相关：结论：与瑞戈非尼单药治疗相比，瑞戈非尼联合 ICIs 能延长 mCRC 患者的 PFS，并显著延长 OS，尤其是男性患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of gastrointestinal oncology Medicine-Oncology

CiteScore

3.20

自引率

0.00%

发文量

171

期刊介绍： ournal of Gastrointestinal Oncology (Print ISSN 2078-6891; Online ISSN 2219-679X; J Gastrointest Oncol; JGO), the official journal of Society for Gastrointestinal Oncology (SGO), is an open-access, international peer-reviewed journal. It is published quarterly (Sep. 2010- Dec. 2013), bimonthly (Feb. 2014 -) and openly distributed worldwide. JGO publishes manuscripts that focus on updated and practical information about diagnosis, prevention and clinical investigations of gastrointestinal cancer treatment. Specific areas of interest include, but not limited to, multimodality therapy, markers, imaging and tumor biology.